EY, the leading global professional services organisation, on Monday released the report ‘Life Sciences 4.0: transforming health care in India’ at BioAsia 2019, Hyderabad. The report highlights how technology is disrupting the health care ecosystem in India as we are entering the Fourth Industrial Revolution (Industry 4.0).





The report states that the Indian healthcare system is being reshaped by three forces: increasing healthcare demand, technological ubiquity and rising patient awareness. The rising prevalence of lifestyle-related diseases and an aging population are the major factors leading to increasing demand for specialised health care in India. However, the Indian healthcare system currently lacks sufficient infrastructure to meet the health care demands of the country. This lack of sufficient health care infrastructure has led to a supply-demand imbalance in the country making healthcare less affordable and accessible for all. While a steep supply-demand imbalance is visible in the country, India at the same time is also one of the fastest technology adopters, globally. Therefore, technological ubiquity and adoption of emerging technologies and tools by health care stakeholders have the potential to offer realistic solutions to meet increasing demand by improving affordability and accessibility. While the healthcare industry in the country has started showing early signs of disruption, it is critical that the life sciences companies get ready to lead the change.





Indian life sciences companies have started taking small, experimental steps on their 4.0 journey. Some of the key areas where the companies have started adopting digital technologies include patient engagement (tools/services for increasing patient awareness about disease/health), physician engagement (tools/services for sharing educational material; interactive portals to connect, etc.), field force effectiveness (technology interfaces such as tabs for e-detailing and easy day-to-day reporting; smart mobile apps for appointment bookings), R&D efficiency (clinical trial data management solutions; technology and data to improve R&D productivity), and supply chain management (use of software to streamline supply and demand and connect buyers to sellers quickly). While the Indian life sciences players are making multiple investments, the activity is fragmented across the value chain and the efforts do not go far enough to reap greater benefits.





Sriram Shrinivasan, Global Emerging Markets Health and Life Sciences Leader and National Health Services Sector Leader, EY said that today, in India and globally, technological advancements are redefining products and enabling customization of services in the healthcare industry. Emerging technologies (e.g., robotics, blockchain, 3D printing and artificial intelligence) and scientific breakthroughs such as gene editing have led to the transformation of life sciences companies’ business models. Going forward, life sciences companies must invest in the three new capabilities: personalization, customer engagement and data literacy.

He said that digital healthcare is one of the key focus areas under the umbrella of the government’s digital initiatives. The Ministry of Health and Family Welfare has several initiatives designed to deliver better health outcomes and the ‘Ayushman Bharat’ program is another initiative towards ensuring better access, improved quality and affordable healthcare to the citizens of India.